Eleven Biotherapeutics (EBIO) Misses Q3 EPS by 17c

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q3 EPS of ($0.50), $0.17 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $68 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• SailPoint Technologies Holdings (SAIL) PT Raised to $25 by Cantor Fitzgerald on Solid Checks
• UBS Assumes Interactive Brokers Group (IBKR) at Neutral, 'A Best-in-Class, Yet Fairly Valued Brokerage'
• Ascendis Pharma (ASND) PT Lowered to $304 at BofA Securities